Product information

577778-58-6/Topiroxostat/FYX 051/High quality/Topiroxostat/FYX 051/99%pure/100% safe delivery/577778-58-6/chemical/topiroxostat/



Boiling point 594.7±60.0 °C(Predicted)

Density 1.45±0.1 g/cm3(Predicted)

Storage conditions -20°C storage

Solubility DMSO: 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)

Acidity coefficient (pKa) 7.47±0.10 (Predicted)

form powder

InChIInChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/ h1-7H,(H,17,18,19)

InChIKeyUBVZQGOVTLIHLH-UHFFFAOYSA-N

SMILESC1(C#N)=NC=CC(C2NN=C(C3C=CN=CC=3)N=2)=C1



Introduction

Topiroxostat (FYX-051), chemical name 5-(2-cyano-4-pyridyl)-3-(4-pyridyl)-1,2,4-triazole, is produced from Japan A non-purine selective xanthine oxidoreductase inhibitor developed by Fuji Pharmaceutical Co., Ltd. that selectively and reversibly inhibits xanthine oxidoreductase and reduces serum uric acid levels.

effect

Topinostat competitively inhibits xanthine oxidoreductase, thereby inhibiting uric acid production. It has no blocking effect on other pyrimidine-purine metabolism enzymes, but shows selective blocking effect on xanthine oxidoreductase. Topinostat has a significant inhibitory effect on both oxidized and reduced XOR, so its uric acid-lowering effect is more powerful and lasting. Therefore, this product can be used to treat chronic hyperuricemia in gout.



Contact me

WhatsAPP: +8615383716096

Signal/Telegram:Helen SHDK

Wickr me:shanghaidekang

Email：helen@pharmsupplier.com

Main products

Company Profile